ZyVersa Therapeutics (ZVSA) Competitors $0.54 -0.01 (-1.33%) Closing price 03:57 PM EasternExtended Trading$0.55 +0.01 (+1.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVSA vs. ENSC, AEON, SNOA, APM, KLTO, DRMA, TTNP, EVOK, TCRT, and CDTShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Ensysce Biosciences (ENSC), AEON Biopharma (AEON), Sonoma Pharmaceuticals (SNOA), Aptorum Group (APM), Klotho Neurosciences (KLTO), Dermata Therapeutics (DRMA), Titan Pharmaceuticals (TTNP), Evoke Pharma (EVOK), Alaunos Therapeutics (TCRT), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Ensysce Biosciences AEON Biopharma Sonoma Pharmaceuticals Aptorum Group Klotho Neurosciences Dermata Therapeutics Titan Pharmaceuticals Evoke Pharma Alaunos Therapeutics Conduit Pharmaceuticals ZyVersa Therapeutics (NASDAQ:ZVSA) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation. Does the media favor ZVSA or ENSC? In the previous week, Ensysce Biosciences had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 4 mentions for Ensysce Biosciences and 3 mentions for ZyVersa Therapeutics. Ensysce Biosciences' average media sentiment score of 1.04 beat ZyVersa Therapeutics' score of 0.66 indicating that Ensysce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZyVersa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ensysce Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in ZVSA or ENSC? 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are owned by institutional investors. 0.2% of ZyVersa Therapeutics shares are owned by insiders. Comparatively, 7.9% of Ensysce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer ZVSA or ENSC? ZyVersa Therapeutics and Ensysce Biosciences both received 3 outperform votes by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote. CompanyUnderperformOutperformZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo VotesEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Which has more volatility and risk, ZVSA or ENSC? ZyVersa Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Which has better valuation and earnings, ZVSA or ENSC? Ensysce Biosciences has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZyVersa TherapeuticsN/AN/A-$98.30MN/AN/AEnsysce Biosciences$2.23M2.31-$10.61M-$6.54-0.33 Is ZVSA or ENSC more profitable? ZyVersa Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. ZyVersa Therapeutics' return on equity of -224.85% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets ZyVersa TherapeuticsN/A -224.85% -103.22% Ensysce Biosciences -179.26%-292.81%-158.83% SummaryEnsysce Biosciences beats ZyVersa Therapeutics on 7 of the 11 factors compared between the two stocks. Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.0626.7119.71Price / SalesN/A251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book0.016.456.774.50Net Income-$98.30M$143.98M$3.23B$248.22M7 Day Performance5.79%2.41%1.80%0.56%1 Month Performance-18.39%4.56%11.10%13.17%1 Year Performance-87.69%-2.67%17.11%7.30% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics0.6266 of 5 stars$0.54-1.3%N/A-87.5%$2.59MN/A0.002News CoverageENSCEnsysce Biosciences0.2418 of 5 stars$2.19+0.9%N/A-78.1%$5.19M$2.23M-0.0810Gap UpAEONAEON Biopharma2.9463 of 5 stars$0.49+3.9%$360.00+73,070.7%-99.6%$5.18MN/A2.735News CoverageSNOASonoma Pharmaceuticals0.2365 of 5 stars$3.17+0.6%N/A+1,533.2%$5.09M$13.97M-0.79180Positive NewsGap UpAPMAptorum Group0.354 of 5 stars$0.93+7.9%N/A-76.6%$4.97M$430,000.000.0030Positive NewsKLTOKlotho NeurosciencesN/A$0.17+5.0%N/AN/A$4.89MN/A0.00N/APositive NewsEarnings ReportHigh Trading VolumeDRMADermata Therapeutics1.3163 of 5 stars$0.79-2.0%$6.00+655.7%-77.5%$4.79MN/A-0.058Positive NewsAnalyst ForecastTTNPTitan Pharmaceuticals0.19 of 5 stars$5.23+2.8%N/A-31.7%$4.78M$180,000.00-1.0010Analyst ForecastGap UpEVOKEvoke Pharma0.1066 of 5 stars$3.11-1.1%N/A-36.3%$4.69M$10.25M-0.284Negative NewsGap UpTCRTAlaunos Therapeutics1.1132 of 5 stars$2.85flatN/A-76.3%$4.67M$10,000.000.0040Positive NewsEarnings ReportGap DownCDTConduit Pharmaceuticals0.7041 of 5 stars$0.41+2.3%N/A-99.9%$4.64MN/A-0.013News CoverageEarnings ReportStock Split Related Companies and Tools Related Companies ENSC Alternatives AEON Alternatives SNOA Alternatives APM Alternatives KLTO Alternatives DRMA Alternatives TTNP Alternatives EVOK Alternatives TCRT Alternatives CDT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVSA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZVSA Stock Free ZVSA Stock Alerts